Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Angiogenesis Inhibitors × Tumor-Agnostic × Clear all
NCT06840119 2026-01-28

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Immunocore Ltd

Phase 1/2 Recruiting
600 enrolled
Tumor-Agnostic

Neoplasms

NCT00093873 2013-05-15

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Amgen

Phase 1 Completed
71 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡